-
ASH China Voice | Prof. Huang Huiqiang: Final Follow-up Report on the Combined Treatment of Relapsed/Refractory Extranodal NK/T-Cell Lymphoma with Pembrolizumab and Sintilimab (SCENT)
From December 9 to December 12, 2023, the 65th American Society of Hematology Annual Meeting (ASH) took place in San Diego. Experts from around the world in the field of hematologic malignancies gathered, presenting a wealth of exciting content. During this conference, Professor Huang Huiqiang and his team from Sun Yat-sen University Cancer Center reported…
-
ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting,…
-
ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma
In the just-concluded 65th American Society of Hematology (ASH) Annual Meeting, CAR-T therapy emerged as a crucial advancement in the treatment of Multiple Myeloma (MM). The only approved BCMA CAR-T in China, Idecabtagene Vicleucel (CT103A), shone brightly. Professor Chunrui Li and her team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,…
-
APASL 2023 | Prof. Rao Huiying: Eliminating HCV, Key Issues That Still Need Attention
Editor’s Note: Chronic HCV infection is a global public health issue. With the widespread use of direct-acting antiviral agents (DAAs), chronic hepatitis C (CHC) has become a curable disease. However,…
-
Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage
Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of “The Voice of China” on the international stage. ASH is one of the largest and most comprehensive international…
-
APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis
Editor’s Note: Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease mediated by autoimmunity, with its pathogenesis not yet fully understood. Traditionally, PBC was thought to predominantly affect Western…
-
2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs
The 65th Annual Meeting of the American Society of Hematology (ASH) recently concluded, with significant contributions in the field of Chronic Myeloid Leukemia (CML) treatment. Professor Jiang Qian and her team from Peking University People’s Hospital presented multiple studies, with abstracts 867 and 869 selected for oral presentations. These reports highlighted the potential of TGRX-678…
-
APASL 2023｜Professor Duan Zhongping: HDV Infection in Chronic HBV Infected Patients at Different Disease Stages
Editor’s Note: Viral hepatitis has imposed a significant disease burden globally. While China’s efforts in controlling viral hepatitis have shown initial success, the large number of chronic viral hepatitis patients…
Connecting Medical Expertise through Media